Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.40 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.40 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31299708 | 1.00 | CYP1A2 (0.48) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| SCHEMBL1402722 | 0.98 | CYP1A2 (0.50) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| SCHEMBL27531796 | 0.93 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| Lithium Ion SCHEMBL5014805 | 0.89 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| SCHEMBL10643440 | 0.85 | CYP1A2 (0.45) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| Propionamide SCHEMBL28316301 | 0.85 | CYP1A2 (0.49) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| Sulfuric Acid SCHEMBL28105325 | 0.84 | DGKA (0.60) | CYP1A2ALDH1A1TSHRDGKAPAM | |
| Sulfuric Acid SCHEMBL5414399 | 0.84 | DGKA (0.60) | CYP1A2ALDH1A1TSHRDGKAPAM | |
| Sulfuric Acid SCHEMBL668669 | 0.84 | DGKA (0.60) | CYP1A2ALDH1A1TSHRDGKAPAM | |
| Sulfuric Acid SCHEMBL31040599 | 0.81 | DGKA (0.57) | CYP1A2ALDH1A1TSHRDGKAPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250171435-A1 | Carbon Linked BCL Inhibitors and Senolytic Compounds and Uses Thereof | Rubedo Life Sciences, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-2292593-A2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| US-7557140-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| US-7407988-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-7183298-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | PROLIFIX LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-6888027-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-05-03 | — | — | US | disclosed |
| US-20050085515-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPO TARGET UK LIMITED, (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | SWK FUNDING LLC | 2004-04-22 | — | — | US | disclosed |
| EP-1328510-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LTD. (GB) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002030879-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | ADORA3 3672/4885PTGS2 1432/4885PDE4D 4217/4885 |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | ADORA3 3672/4885PTGS2 1432/4885PDE4D 4217/4885 |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | ADORA3 3672/4885PTGS2 1432/4885PDE4D 4217/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ADORA3 4819/4885PTGS2 4597/4885PDE4D 4275/4885 |
| US-20250171435-A1 | Carbon Linked BCL Inhibitors and Senolytic Compounds and Uses Thereof | BCL2, BCL2A1, BCL2L1 | ADORA3 4426/4885PTGS2 718/4885PDE4D 4342/4885 |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC2 | ADORA3 3889/4885PTGS2 1107/4885PDE4D 4383/4885 |
| US-20050085515-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | ADORA3 3672/4885PTGS2 1432/4885PDE4D 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.